{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:42:10Z","timestamp":1784864530841,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA257505"],"award-info":[{"award-number":["R01CA257505"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110821"],"award-info":[{"award-number":["W81XWH2110821"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["MRA827624"],"award-info":[{"award-number":["MRA827624"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U54CA209891"],"award-info":[{"award-number":["5U54CA209891"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101027731"],"award-info":[{"award-number":["101027731"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["800924"],"award-info":[{"award-number":["800924"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jbc.2025.110712","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:44:40Z","timestamp":1757605480000},"page":"110712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma"],"prefix":"10.1016","volume":"301","author":[{"given":"Simone","family":"Lubrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6599-7994","authenticated-orcid":false,"given":"Rodolfo Daniel","family":"Cervantes-Villagrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-2188","authenticated-orcid":false,"given":"Nadia","family":"Arang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Officer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-8333","authenticated-orcid":false,"given":"Sendi Rafael","family":"Adame-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5982-1464","authenticated-orcid":false,"given":"Gabriela","family":"Cuesta-Margolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Aplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4482","authenticated-orcid":false,"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.110712_bib1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbc.2025.110712_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110712_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/PPO.0b013e31824bd256","article-title":"Metastatic uveal melanoma: biology and emerging treatments","volume":"18","author":"Woodman","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.jbc.2025.110712_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jbc.2025.110712_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.110712_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2025.110712_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CMR.0000000000000121","article-title":"GNAQ and GNA11 mutations in uveal melanoma","volume":"24","author":"Shoushtari","year":"2014","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jbc.2025.110712_bib8","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2025.110712_bib9","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.jbc.2025.110712_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2018.08.005","article-title":"How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma","volume":"103","author":"Steeb","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbc.2025.110712_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccell.2019.01.009","article-title":"A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal Melanoma oncogene controls the Hippo pathway through FAK","volume":"35","author":"Feng","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110712_bib12","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1158\/1078-0432.CCR-20-3363","article-title":"Synthetic lethal screens reveal cotargeting FAK and MEK as a multimodal precision therapy for GNAQ-Driven uveal melanoma","volume":"27","author":"Paradis","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.110712_bib13","article-title":"High-throughput chemogenetic drug screening reveals PKC-RhoA\/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma","volume":"4","author":"Arang","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.jbc.2025.110712_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082280","article-title":"FAK inhibitor-based combinations with MEK or PKC inhibitors trigger synergistic Antitumor effects in uveal melanoma","volume":"15","author":"Tarin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jbc.2025.110712_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2025.110712_bib16","doi-asserted-by":"crossref","first-page":"CT260","DOI":"10.1158\/1538-7445.AM2024-CT260","article-title":"Abstract CT260: a phase II trial of defactinib combined with avutometinib in patients with metastatic uveal melanoma","volume":"84","author":"Seedor","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110712_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.jbc.2025.110712_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.trecan.2022.10.004","article-title":"Endogenous and imposed determinants of apoptotic vulnerabilities in Cancer","volume":"9","author":"Sarosiek","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jbc.2025.110712_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbc.2025.110712_bib20","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)81728-6","article-title":"Apoptotic pathways: the roads to ruin","volume":"94","author":"Green","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2025.110712_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1478-811X-8-31","article-title":"PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration","volume":"8","author":"Chaitanya","year":"2010","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.jbc.2025.110712_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","article-title":"FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma","volume":"43","author":"Lubrano","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.110712_bib23","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.041619798","article-title":"Solution structure of the antiapoptotic protein bcl-2","volume":"98","author":"Petros","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2025.110712_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbamcr.2003.08.012","article-title":"Structural biology of the Bcl-2 family of proteins","volume":"1644","author":"Petros","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2025.110712_bib25","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-16-1248","article-title":"Finally, an apoptosis-targeting therapeutic for cancer","volume":"76","author":"Croce","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2025.110712_bib26","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2024.42.16_suppl.9510","article-title":"A phase 2 safety and efficacy study of neoadjuvant\/adjuvant darovasertib for localized ocular melanoma","volume":"42","author":"Joshua","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbc.2025.110712_bib27","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.110712_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbc.2025.110712_bib29","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination targeted therapy in relapsed diffuse large B-Cell lymphoma","volume":"390","author":"Melani","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbc.2025.110712_bib30","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jbc.2025.110712_bib31","first-page":"587","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets genomics","volume":"20","author":"Zheng","year":"2022","journal-title":"Proteomics Bioinform."},{"key":"10.1016\/j.jbc.2025.110712_bib32","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-24-3785","article-title":"Genome-Wide CRISPR screening reveals that mTOR inhibition initiates ferritinophagy and ferroptosis in head and neck","volume":"85","author":"Koshizuka","year":"2025","journal-title":"Cancer Cancer Res."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825025645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825025645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:47:28Z","timestamp":1777416448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825025645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0021925825025645"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110712","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.110712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"110712"}}